Page 200 - HIV/AIDS Guidelines
P. 200

Table 15b. Drug Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors* and Other
            Drugs  (Page 1 of 6)

            This table provides information relating to PK interactions between NNRTIs and non-ARV drugs. For interactions among
            ARV agents and for dosing recommendations, refer to Table 16b.

            *DLV is not included in this table. Please refer to the DLV FDA package insert for information regarding DLV drug interactions.



                                                 Effect on NNRTI or
               Concomitant Drug      NNRTI a     Concomitant Drug         Dosing Recommendations and Clinical
                  Class/Name                                                           Comments
                                                  Concentrations
             Acid Reducers

             Antacids               RPV       ↓ RPV expected when given  Give antacids at least 2 hours before or at least 4 hours
                                              simultaneously           after RPV.

             H2 Receptor Antagonists  RPV     ↓ RPV                    Give H2 receptor antagonists at least 12 hours before
                                                                       or at least 4 hours after RPV.

             Proton Pump Inhibitors  RPV      ↓ RPV                    Contraindicated. Do not coadminister.
             (PPI)
             Anticoagulants/Antiplatelets

                                    EFV, NVP  ↑ or ↓ warfarin possible  Monitor INR and adjust warfarin dose accordingly.
             Warfarin
                                    ETR       ↑ warfarin possible      Monitor INR and adjust warfarin dose accordingly.

             Clopidogrel            ETR       ↓ activation of clopidogrel  ETR may prevent metabolism of clopidogrel (inactive)
                                              possible                 to its active metabolite. Avoid coadministration, if
                                                                       possible.

             Anticonvulsants
                                    EFV       carbamazepine + EFV:     Monitor anticonvulsant and EFV levels or, if possible,
                                              carbamazepine AUC ↓ 27%  use alternative anticonvulsant to those listed.
                                              and EFV AUC ↓ 36%
                                              phenytoin + EFV: ↓ EFV and
                                              ↓ phenytoin possible
             Carbamazepine          ETR       ↓ anticonvulsant and ETR  Do not coadminister. Consider alternative
             Phenobarbital                    possible                 anticonvulsant.
             Phenytoin
                                    NVP       ↓ anticonvulsant and NVP  Monitor anticonvulsant and NVP levels and virologic
                                              possible                 responses or consider alternative anticonvulsant.

                                    RPV       ↓ RPV possible           Contraindicated. Do not coadminister. Consider
                                                                       alternative anticonvulsant.
             Antidepressants

             Bupropion              EFV       bupropion AUC ↓ 55%      Titrate bupropion dose based on clinical response.
             Paroxetine             EFV, ETR  No significant effect    No dosage adjustment necessary.
             Sertraline             EFV       sertraline AUC ↓ 39%     Titrate sertraline dose based on clinical response.









            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents        K-30

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   195   196   197   198   199   200   201   202   203   204   205